Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
János Tajti, Zsófia Majláth, Délia Szok, Anett Csáti & László Vécsei. (2015) Drug safety in acute migraine treatment. Expert Opinion on Drug Safety 14:6, pages 891-909.
Read now
Read now
B. K. Sharma, P. Singh, P. Pilania, M. Shekhawat & Y.S. Prabhakar. (2012) QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: simple structural fragments as potential modulators of activity. Journal of Enzyme Inhibition and Medicinal Chemistry 27:2, pages 249-260.
Read now
Read now
Gunther Haag. (2010) Headache and medication overuse: are clinical case series appropriate to reveal differential risks of different medications?. Expert Opinion on Drug Safety 9:3, pages 397-406.
Read now
Read now
Bruno P Imbimbo. (2009) An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opinion on Investigational Drugs 18:8, pages 1147-1168.
Read now
Read now
Articles from other publishers (18)
Zizheng Zhang, Ping He, Huayan Yao, Renjie Jing, Wen Sun, Ping Lu, Yanbin Xue, Jiying Qi, Bin Cui, Min Cao & Guang Ning. (2023) A network-based study reveals multimorbidity patterns in people with type 2 diabetes. iScience 26:10, pages 107979.
Crossref
Crossref
Michel BurnierSr.Sr.. 2022. Nutritional Management of Renal Disease. Nutritional Management of Renal Disease
313
328
.
Н.А. Михайловская & Т.Н. Слободин. (2020) Nonsteroidal Anti-Inflammatory Drugs: Risks and Benefits. Неврология и нейрохирургия. Восточная Европа:3, pages 414-434.
Crossref
Crossref
Nicola Veronese, Cyrus Cooper, Jean-Yves Reginster, Marc Hochberg, Jaime Branco, Olivier Bruyère, Roland Chapurlat, Nasser Al-Daghri, Elaine Dennison, Gabriel Herrero-Beaumont, Jean-François Kaux, Emmanuel Maheu, René Rizzoli, Roland Roth, Lucio C. Rovati, Daniel Uebelhart, Mila Vlaskovska & André Scheen. (2019) Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism 49:1, pages 9-19.
Crossref
Crossref
A V Naumov, O N Tkacheva & N O Khovasova. (2019) Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. Terapevticheskii arkhiv 91:1, pages 108-113.
Crossref
Crossref
Christine Li Ling Lau, Sook Tyng Chan, Manimegahlai Selvaratanam, Hui Wen Khoo, Adeline Yi Ling Lim, Pilar Modamio, Eduardo L. Mariño & Ignacio Segarra. (2015) Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently. Fundamental & Clinical Pharmacology 29:4, pages 404-416.
Crossref
Crossref
L.J. Miwa, M. Maneno & Judith K. Jones. 2015. Ibuprofen. Ibuprofen
450
497
.
Wolfgang W. Bolten, M. Gross, T. Brabant, Vivien Weck & J. Labenz. (2013) Der Fokus liegt auf der individuellen Risikobewertung. MMW - Fortschritte der Medizin 155:3, pages 59-63.
Crossref
Crossref
T. M. MacDonald, D. Richard, K. Lheritier & G. Krammer. (2010) The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. International Journal of Clinical Practice 64:6, pages 746-755.
Crossref
Crossref
Martin R. Farlow. 2010. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Brocklehurst's Textbook of Geriatric Medicine and Gerontology
411
420
.
W. Jaksch, C. Dejaco & M. Schirmer. (2008) 4 years after withdrawal of rofecoxib: where do we stand today?. Rheumatology International 28:12, pages 1187-1195.
Crossref
Crossref
Michael E. FarkouhFreek W. A. VerheugtSean RulandHoward KirshnerRaban JegerXavier GittonGerhard KrammerKirstin StrickerPeter SallstigBernhard MelleinPatrice MatchabaJames H. Chesebro. (2008) A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. The Journal of Clinical Hypertension 10:8, pages 592-602.
Crossref
Crossref
Aurelio Orjales, Ramón Mosquera, Beatriz López, Roberto Olivera, Luis Labeaga & M. Teresa Núñez. (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorganic & Medicinal Chemistry 16:5, pages 2183-2199.
Crossref
Crossref
Li‐Chia Chen & Darren M Ashcroft. (2007) Risk of myocardial infarction associated with selective COX‐2 inhibitors: Meta‐analysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety 16:7, pages 762-772.
Crossref
Crossref
Taha Okan, Ismail Sari, Servet Akar, Hasan Cece, Ozhan Goldeli, Sema Guneri & Nurullah Akkoc. (2007) Ventricular Diastolic Functions of Ankylosing Spondylitis Patients by Using Conventional Pulsed?Wave Doppler, Myocardial Performance Index, and Tissue Doppler Imaging. Echocardiography 0:0, pages 070619173248003-???.
Crossref
Crossref
Martin R. Farlow. (2007) ALZHEIMER'S DISEASE. CONTINUUM: Lifelong Learning in Neurology 13, pages 39-68.
Crossref
Crossref
Judith S. HochmanNirav R. Shah. (2006) What Price Pain Relief?. Circulation 113:25, pages 2868-2870.
Crossref
Crossref
Sabine Grösch, Thorsten Jürgen Maier, Susanne Schiffmann & Gerd Geisslinger. (2006) Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI: Journal of the National Cancer Institute 98:11, pages 736-747.
Crossref
Crossref